Liquid chromatography/mass spectrometry‐based plasma metabolic profiling study of escitalopram in subjects with major depressive disorder

Liquid chromatography‐mass spectrometry (LC‐MS) method revealed the plasma metabolite profiles in major depressive disorder patients treated with escitalopram (ECTP) (n = 7). Depression severity was assessed according to the 17‐item Hamilton Depression Rating Scale. Metabolic profiles were derived f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of mass spectrometry. 2018-05, Vol.53 (5), p.385-399
Main Authors: Bandu, Raju, Lee, Hyun Jeong, Lee, Hyeong Min, Ha, Tae Hyon, Lee, Heon‐Jeong, Kim, Se Joo, Ha, Kyooseob, Kim, Kwang Pyo
Format: Article
Language:English
Subjects:
Blood
Blood plasma
Chromatography
Citalopram
escitalopram
Hydrogen-deuterium exchange
LC/ESI‐MS/MS
Liquid chromatography
major depressive disorder subjects
Mass spectrometry
Mass spectroscopy
Mental depression
Metabolism
Metabolites
Molecular chains
Pharmacology
plasma
Profiles
Scientific imaging
Spectroscopy
Therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liquid chromatography‐mass spectrometry (LC‐MS) method revealed the plasma metabolite profiles in major depressive disorder patients treated with escitalopram (ECTP) (n = 7). Depression severity was assessed according to the 17‐item Hamilton Depression Rating Scale. Metabolic profiles were derived from major depressive disorder subject blood samples collected after ECTP treatment. Blood plasma was separated and processed in order to effectively extract metabolites, which were then analyzed using LC‐MS. We identified 19 metabolites and elucidated their structures using LC‐tandem MS (LC‐MS/MS) combined with elemental compositions derived from accurate mass measurements. We further used online H/D exchange experiments to verify the structural elucidations of each metabolite. Identifying molecular metabolites may provide critical insights into the pharmacological and clinical effects of ECTP treatment and may also provide useful information informing the development of new antidepressant treatments. These detailed plasma metabolite analyses may also be used to identify optimal dose concentrations in psychopharmacotherapeutic treatment through drug monitoring, as well as forming the basis for response predictions in depressed subjects.
ISSN:1076-5174
1096-9888
DOI:10.1002/jms.4070